Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications
Open Access
- 23 June 2020
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (21) , 5557-5566
Abstract
Small-molecule targeted therapies have demonstrated outstanding potential in the clinic. These drugs are designed to minimize adverse effects by selectively attacking cancer cells while exerting minimal damage to normal cells. Although initial response to targeted therapies may be high, yielding positive response rates and often improving survival for an important percentage of patients, resistance often limits long-term effectiveness. On the other hand, immunotherapy has demonstrated durable results, yet for a limited number of patients. Growing evidence indicates that some targeted agents can modulate different components of the antitumor immune response. These include immune sensitization by inhibiting tumor cell–intrinsic immune evasion programs or enhancing antigenicity, as well as direct effects on immune effector and immunosuppressive cells. The combination of these two approaches, therefore, has the potential to result in synergistic and durable outcomes for patients. In this review, we focus on the latest advances on integrating immunotherapy with small-molecule targeted inhibitors. In particular, we discuss how specific oncogenic events differentially affect immune response, and the implications of these findings on the rational design of effective combinations of immunotherapy and targeted therapies.Keywords
Funding Information
- Susan G. Komen (PDF16376814)
- DOD CDMRP (BC171657)
- NIH (P50 CA168504, P50 CA165962, R35 CA210057)
This publication has 74 references indexed in Scilit:
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitorsJournal of Clinical Investigation, 2013
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell ImmunotherapyCancer Research, 2012
- A Requirement of STAT3 DNA Binding Precludes Th-1 Immunostimulatory Gene Expression by NF-κB in TumorsCancer Research, 2011
- SMAD4-dependent barrier constrains prostate cancer growth and metastatic progressionNature, 2011
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte FunctionCancer Research, 2010
- STATs in cancer inflammation and immunity: a leading role for STAT3Nature Reviews Cancer, 2009
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersNew England Journal of Medicine, 2009
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNature Medicine, 2006
- Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cellsNature Medicine, 2003